Neuberg Diagnostics is planning to launch an IPO within the next six months. The company has initiated the discussion with the bankers for a float of around USD 350 million (~INR 3,270 crore), according to a report. The Chennai-headquartered diagnostics chain has been in the market, preparing for a 2026 listing, aligning deal timing with operating scale-up and market conditions.
Market chatter around the company’s timeline has firmed up since late 2025, when reports said Neuberg was eyeing a 2026 debut with a potential USD 350-million raise. Management has previously acknowledged that an IPO is one of the options on the table as the group consolidates businesses and expands its integrated diagnostics footprint. Any final size and timing remain subject to regulatory clearances and market conditions.
Neuberg Diagnostics IPO: Funding Runway & Network Scale
The company strengthened its balance sheet in January 2025 with INR 940 crore from Kotak Alternate Asset Managers’ Strategic Situations India Fund II, capital earmarked for inorganic growth and to accelerate IPO readiness. At the time, deal discussions implied a valuation band of INR 6,000–7,000 crore for Neuberg.
Neuberg says it operates more than 250 laboratories and 10,000 touch points across about 250 cities, positioning itself among India’s larger diagnostic platforms by reach. Over the past year, the group has pushed deeper into integrated pathology-and-radiology centres—most notably through a joint venture with Maharashtra-based Star Imaging to scale centres across the state.
Neuberg Diagnostics IPO: Management Call
“As we prepare for an IPO, we remain committed to making high-quality diagnostics accessible to all,” Founder and Managing Director GSK Velu said last year while announcing the Kotak investment.
“The investment reflects our confidence in Neuberg’s vision and potential,” added Rahul Shah, partner at Kotak Alternate Asset Managers, underscoring investor backing for the scale-up.
Sector Backdrop & Peers
Diagnostics remains a structurally growing category, supported by rising chronic disease burden and higher testing penetration. Sector data cited in company communications peg the Indian diagnostics market at about USD 13 billion in 2023, with expectations to double by 2028—tailwinds that have sustained investor appetite for quality platforms.
For context, earlier public-market listings from listed peers raised between a few hundred crore to over INR 1,200 crore—Dr Lal PathLabs (INR 638 crore), Thyrocare (INR 479 crore) and Metropolis Healthcare (INR 1,204 crore)—providing useful comparables on float sizing relative to scale and market windows. Neuberg’s mooted USD 350-million offer, if executed as indicated, would be significantly larger than those earlier floats.
Neuberg Diagnostics IPO Key Highlights
- Neuberg Diagnostics IPO timeline: Within six months (by September 2026), subject to clearances and markets.
- Indicative size: About USd 350 million, discussions with bankers reported in November 2025.
- Neuberg Diagnostics Pre-IPO funding: INR 940 crore from Kotak Alternate Asset Managers.
- Network: 250+ labs, 10,000+ touch points across ~250 cities.
- Expansion: JV with Star Imaging to scale integrated centres across Maharashtra.
Diagnostics Sector IPO Performance
In the last eight years, five IPOs have come from the diagnostics sector. However, their performance has not been particularly impressive, and investors have incurred losses in 3 out of 2 IPOs.
| Company Name | Listing Date | Allotment Price | % Listing P/L | % CMP P/L |
| Nephrocare | 12/17/2025 | 460 | 2.45 | 17.13 |
| Suraksha Diagnostic | 12/6/2024 | 441 | (5.39) | (41.04) |
| Vijaya Diagnostic | 9/14/2021 | 531 | 16.78 | 72.45 |
| Krsnaa Diagnostics | 8/16/2021 | 954 | 3.46 | (37.46) |
| Metropolis Healthcare | 4/15/2019 | 880 | 9.07 | (48.86) |
Bottomline: Neuberg Diagnostics IPO window suggests a well-telegraphed push to public markets in 2026. Execution now hinges on DRHP filing, market conditions, and the final construct of the offer; if the reported USD 350-million size holds, the float would mark one of the larger primary issuances from India’s diagnostics space.
Rajat Bhati has a strong technical background and 5 years of experience in the stock market. He focuses on equity research, technical analysis, IPO valuations, and risk management, helping investors make clearer, data-backed decisions. Today, he works full-time to educate people about the opportunities in IPO market.